Iovance Biotherapeutics Inc (NAS:IOVA)
$ 9.32 -0.08 (-0.85%) Market Cap: 2.84 Bil Enterprise Value: 2.52 Bil PE Ratio: 0 PB Ratio: 3.67 GF Score: 39/100

Iovance Biotherapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 11, 2021 / 06:50PM GMT
Release Date Price: $35.56 (+5.49%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Great. Good afternoon or good morning, anywhere you are. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech equity analysts at Barclays. I just want to thank everyone for taking time out of their day today to listen to Iovance.

And if you have questions for institutional investors, please e-mail me to [email protected], or you can ping me on Bloomberg. It gives me great pleasure to introduce Iovance. We've got Maria Fardis, CEO. And just as a kind of introductory question, if you could maybe just talk through the differentiation and kind of the core competencies of Iovance in the oncology T cell space. Thank you.

Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director

Certainly. Thank you, Peter, for the invitation. Good afternoon, good morning to you.

So Iovance is developing a tumor infiltrating lymphocyte for treatment of solid tumors. These are cells that normally would come to the site

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot